Literature DB >> 14590568

Neuropsychological sequelae in a series of patients with end-stage cystic fibrosis: lung transplant evaluation.

W D Crews1, A L Jefferson, D K Broshek, J T Barth, M K Robbins.   

Abstract

There has been a relative absence of studies that examine the neuropsychological profiles of patients suffering from cystic fibrosis. Data are presented here for 18 individuals with end-stage cystic fibrosis who were also potential candidates for lung transplantation. Neuropsychological test results indicated a diversity of memory and executive control deficits, the most frequent of which were immediate and delayed free recall and retrieval impairments on a memory measure involving noncontextual verbal material. The majority of this sample of patients suffering from cystic fibrosis also exhibited clinically significant elevations on the Minnesota Multiphasic Personality Inventory-2 and Minnesota Multiphasic Personality Inventory-Adolescent (MMPI-2/MMPI-A), which are suggestive of heightened levels of psychological distress (e.g., depressive symptomatology) and multiple somatic complaints. These findings are discussed in light of factors associated with end-stage cystic fibrosis. Implications for clinical practice and future research are also provided.

Entities:  

Year:  2000        PMID: 14590568

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  2 in total

1.  Neuropsychological dysfunction in patients with end-stage pulmonary disease: lung transplant evaluation.

Authors:  W David Crews; Angela L Jefferson; Donna K Broshek; Robert D Rhodes; John Williamson; Amy M Brazil; Jeffrey T Barth; Mark K Robbins
Journal:  Arch Clin Neuropsychol       Date:  2003-05       Impact factor: 2.813

2.  Neuropsychological dysfunction in patients suffering from end-stage chronic obstructive pulmonary disease.

Authors:  W D Crews; A L Jefferson; T Bolduc; J B Elliott; N M Ferro; D K Broshek; J T Barth; M K Robbins
Journal:  Arch Clin Neuropsychol       Date:  2001-10       Impact factor: 2.813

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.